$heff's $tation of $tocks & $olid DD

[spartakis1]

BMY Abstracts for ASCO released Wed. 5pm Will be a lot of focus on PD-1 targeting therapy's. Nivolumab being one of them. Interested to see what happens, not sure if will hold or not (most likely will) seeing how the stock reacts next week. Macd about to cross signal line, Macd hista moving up, momentum over 100, 3&5SMA heading up with 3 over 5, price > 10&20SMA. It has held up well for all the bio drama.
Last ASCO we had a 17% run in 18 days.

[/URL]" rel="nofollow" target="_blank" >insert-text-here